rivaroxaban + dabigatran etexilate + clarithromycin (Assistance publique - Hôpitaux de Paris)

R + D + C + R-Assistance Publique - Hôpitaux de Paris-thromboembolism refers to a specific drug combination and sequence protocol used in clinical research conducted by Assistance Publique - Hôpitaux de Paris. The regimen consists of two direct oral anticoagulants (DOACs)—rivaroxaban (a Factor Xa inhibitor) and dabigatran etexilate (a direct thrombin inhibitor)—and the macrolide antibiotic clarithromycin. This combination was primarily utilized in the DRIVING trial (Genetics and Anticoagulants) to investigate the impact of genetic polymorphisms, particularly in the ABCB1 gene (encoding P-glycoprotein), on the pharmacokinetics and intestinal absorption of DOACs. Clarithromycin serves as a pharmacological tool in this context, acting as a potent inhibitor of both P-glycoprotein (P-gp) and the CYP3A4 enzyme to characterize drug-drug interactions and the role of efflux transporters in anticoagulant bioavailability. The study aimed to improve the safety and efficacy of thromboembolism prevention by understanding individual variability in drug response.

Brand names

XareltoPradaxaBiaxin

Other names

rivaroxaban + dabigatran + clarithromycinR + D + C + R-Assistance Publique - Hôpitaux de Paris-thromboembolism